Dihydrocodeine 30mg tablets

Šalis: Didžioji Britanija

kalba: anglų

Šaltinis: MHRA (Medicines & Healthcare Products Regulatory Agency)

Nusipirk tai dabar

Pakuotės lapelis Pakuotės lapelis (PIL)
25-12-2022
Prekės savybės Prekės savybės (SPC)
30-11--0001

Veiklioji medžiaga:

Dihydrocodeine tartrate

Prieinama:

M & A Pharmachem Ltd

ATC kodas:

N02AA08

INN (Tarptautinis Pavadinimas):

Dihydrocodeine tartrate

Dozė:

30mg

Vaisto forma:

Oral tablet

Vartojimo būdas:

Oral

Klasė:

Schedule 5 (CD Inv)

Recepto tipas:

Valid as a prescribable product

Produkto santrauka:

BNF: 04070200; GTIN: 5056205100200 5056205100217

Pakuotės lapelis

                                5HDGDOORIWKLVOHDIOHWFDUHIXOO\EHIRUH\RXVWDUWWDNLQJ
WKLVPHGLFLQHEHFDXVHLWFRQWDLQVLPSRUWDQWLQIRUPDWLRQ
IRU\RX


.HHSWKLVOHDIOHW
                                
                                Perskaitykite visą dokumentą
                                
                            

Prekės savybės

                                OBJECT 1
DIHYDROCODEINE 30MG TABLETS
Summary of Product Characteristics Updated 20-Jun-2019 | M & A
Pharmachem Ltd
•
1. Name of the medicinal product
•
2. Qualitative and quantitative composition
•
3. Pharmaceutical form
•
4. Clinical particulars
•
4.1 Therapeutic indications
•
4.2 Posology and method of administration
•
4.3 Contraindications
•
4.4 Special warnings and precautions for use
•
4.5 Interaction with other medicinal products and other forms of
interaction
•
4.6 Fertility, pregnancy and lactation
•
4.7 Effects on ability to drive and use machines
•
4.8 Undesirable effects
•
4.9 Overdose
•
5. Pharmacological properties
•
5.1 Pharmacodynamic properties
•
5.2 Pharmacokinetic properties
•
5.3 Preclinical safety data
•
6. Pharmaceutical particulars
•
6.1 List of excipients
•
6.2 Incompatibilities
•
6.3 Shelf life
•
6.4 Special precautions for storage
•
6.5 Nature and contents of container
•
6.6 Special precautions for disposal and other handling
•
7. Marketing authorisation holder
•
8. Marketing authorisation number(s)
•
9. Date of first authorisation/renewal of the authorisation
•
10. Date of revision of the text
1. Name of the medicinal product
Dihydrocodeine Tablets BP 30 mg
2. Qualitative and quantitative composition
Each tablet contains 30 mg Dihydrocodeine Tartrate
3. Pharmaceutical form
Tablet
4. Clinical particulars
4.1 Therapeutic indications
Dihydrocodeine tablets are indicated for the relief of moderate to
severe pain.
4.2 Posology and method of administration
For oral administration
The analgesic effect is not materially enhanced by increasing the dose
above that recommended below; in
severe cases the interval between doses should be reduced to obtain
the requisite analgesic cover.
Dihydrocodeine tablets are best taken with or after food.
Adults and children over 12 years: 1 tablet every four to six hours or
at the discretion of the practitioner.
Maximum dose in 24 hours 180mg (6 tablets).
Elderly
A reduced adult dose is recommended, at the 
                                
                                Perskaitykite visą dokumentą
                                
                            

Ieškokite perspėjimų, susijusių su šiuo produktu

Peržiūrėti dokumentų istoriją